Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tenecteplase before interhospital transfer for EVT in anterior circulation LVO (4.5–24h)
ChiCTR2500112396Phase 3Not yet recruiting
- Sponsor
- Xuanwu Hospital
- Start
- Nov 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial of tenecteplase in ischemic stroke (2 arms), sponsored by Xuanwu Hospital. Primary endpoint: ordinal mRS score at 90 days. Planned start Nov 2025; status: not yet recruiting.
02
Drugs
tenecteplase
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on ChiCTR2500112396.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500112396.